Ubiquitination of transcription factors in cancer: unveiling therapeutic potential
Molecular Oncology · 2025-08 · 19 (8) · 2174-2195
DOI: 10.1002/1878-0261.70033 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Oncology, online erschienen am 14.04.2025. Verfasst von Dongha Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, College of Medicine, The Catholic University of Korea, Seoul, Korea. Hauptthemen laut MEDLINE: Ubiquitination, Neoplasms, Transcription Factors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and ICT, South Korea, Korea Research Institute of Chemical Technology, National Research Foundation of Korea.
Abstract (Originalsprache)
Transcription factors, pivotal in gene expression regulation, are essential in cancer progression. Their function is meticulously regulated by post‐translational modifications, including ubiquitination. This process, which marks proteins for degradation, can either enhance or inhibit the function of transcription factors, contingent on the context. In cancers, dysregulated ubiquitination of transcription factors contributes to the hallmark of uncontrolled growth and survival of tumors. For example, tumor suppressors such as p53 might be degraded prematurely due to abnormal ubiquitination, causing genomic instability. On the other hand, oncogenic transcription factors may gain stability via ubiquitination, thus facilitating tumorigenesis. Targeting the ubiquitin–proteasome system (UPS) therefore could be a viable therapeutic approach in cancer. Emerging treatments aim to block the ubiquitination of oncogenic transcription factors or to stabilize tumor suppressors. This review underscores the critical impact of transcription factor‐altered ubiquitination on cancer progression. Additionally, it outlines innovative therapeutic approaches that involve inhibitors or drugs directed at specific ubiquitin E3 ligases and deubiquitinases (DUBs) that regulate transcription factor activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Therapeutics and Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon, Korea.
- Department of Medicinal Chemistry and Pharmacology, University of Science and Technology, Daejeon, Korea.
- Creative Research Initiatives Center for Epigenetic Code and Diseases, School of Biological Sciences, Seoul National University, Korea.
ORCID-Profile: Dongha Kim, Hye Jin Nam, Sung Hee Baek
Förderung
- Ministry of Science and ICT, South Korea
- Korea Research Institute of Chemical Technology
- National Research Foundation of Korea
Zitieren
APA
Kim, D., Nam, H. J., & Baek, S. H. (2025). Ubiquitination of transcription factors in cancer: unveiling therapeutic potential. Molecular Oncology, 19(8), 2174-2195. https://doi.org/10.1002/1878-0261.70033
Vancouver
Kim D, Nam HJ, Baek SH. Ubiquitination of transcription factors in cancer: unveiling therapeutic potential. Molecular Oncology. 2025;19(8):2174-2195. doi:10.1002/1878-0261.70033
BibTeX
@article{Kim2025,
author = {Kim, Dongha and Nam, Hye Jin and Baek, Sung Hee},
title = {Ubiquitination of transcription factors in cancer: unveiling therapeutic potential},
journal = {Molecular Oncology},
year = {2025},
volume = {19},
number = {8},
pages = {2174--2195},
doi = {10.1002/1878-0261.70033}
}
EUVIMED